IMUNON INC. - COMMON STOCK

IMUNON to Host R&D Day on September 18th

28 Aug 2024 08:30:00 By Nasdaq GlobeNewswire

IMUNON Reports Second Quarter 2024 Financial Results and Provides a Business Update

14 Aug 2024 08:00:00 By Nasdaq GlobeNewswire

IMUNON to Hold Second Quarter 2024 Financial Results and Business Update Conference Call on Wednesday, August 14, 2024

07 Aug 2024 17:04:00 By Nasdaq GlobeNewswire

IMUNON Announces $10 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

31 Jul 2024 08:00:00 By Nasdaq GlobeNewswire

IMUNON Announces 11.1 Month Increase in Overall Survival in Patients with Newly Diagnosed, Advanced Ovarian Cancer Treated with IMNN-001

30 Jul 2024 08:00:00 By Nasdaq GlobeNewswire

IMUNON to Report Topline Results from the Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer Tomorrow

29 Jul 2024 16:05:00 By Nasdaq GlobeNewswire

IMUNON Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer

24 Jun 2024 08:30:00 By Nasdaq GlobeNewswire

First Participants Vaccinated in IMUNON’s IMNN-101 Phase 1 Clinical Trial

05 Jun 2024 08:30:00 By Nasdaq GlobeNewswire

Abstract on Phase 2 Study with IMUNON’s IMNN-001 Plus Bevacizumab Accepted for Presentation at the American Society of Clinical Oncology Annual Meeting

15 May 2024 08:30:00 By Nasdaq GlobeNewswire

IMUNON Announces Site Activation for IMNN-101 Phase 1 Vaccine Study

13 May 2024 09:00:00 By Nasdaq GlobeNewswire

IMUNON Reports First Quarter 2024 Financial Results and Provides Business Update

13 May 2024 08:00:01 By Nasdaq GlobeNewswire

IMUNON Appoints Director Dr. Stacy R. Lindborg as President and CEO

08 May 2024 08:00:00 By Nasdaq GlobeNewswire

IMUNON to Hold First Quarter 2024 Financial Results and Business Update Conference Call on Monday, May 13, 2024

06 May 2024 11:00:00 By Nasdaq GlobeNewswire

IMUNON’s IND Application Cleared to Begin Human Testing of IMNN-101

18 Apr 2024 08:30:00 By Nasdaq GlobeNewswire

IMUNON Reports Compliance with Nasdaq Listing Requirements

11 Apr 2024 08:00:00 By Nasdaq GlobeNewswire

IMUNON Reports 2023 Financial Results and Provides Business Update

28 Mar 2024 08:00:00 By Nasdaq GlobeNewswire

IMUNON Receives $1.3 Million from Sale of its New Jersey Net Operating Losses

25 Mar 2024 08:30:00 By Nasdaq GlobeNewswire

IMUNON to Hold 2023 Financial Results and Business Update Conference Call on Thursday, March 28, 2024

21 Mar 2024 17:00:00 By Nasdaq GlobeNewswire

IMUNON Files IND Application to Begin Human Testing of IMNN-101

13 Mar 2024 08:00:00 By Nasdaq GlobeNewswire

IMUNON Announces Leadership Change

12 Mar 2024 17:00:00 By Nasdaq GlobeNewswire